Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Intellipharmaceutics International Inc. (NASDAQ: IPCI).

Full DD Report for IPCI

You must become a subscriber to view this report.


Recent News from (NASDAQ: IPCI)

Intellipharmaceutics Announces Resignation of Chief Financial Officer
TORONTO, ON / ACCESSWIRE / November 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rele...
Source: ACCESSWIRE
Date: November, 05 2018 18:10
Abuse-Deterrent Opioids: A Business Answer To The Opioid Abuse Crisis
Context The widespread abuse of opioids has been a national tragedy. It has contributed to the deaths of thousands and led to billions of dollars spent in search of comprehensive remedies. To date, no single solution has been completely effective in reducing the consequences of opioid abuse,...
Source: SeekingAlpha
Date: September, 13 2018 11:41
Intellipharmaceutics Announces One-for-10 Reverse Stock Split
TORONTO, ONTARIO / ACCESSWIRE / September 13 , 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and ta...
Source: ACCESSWIRE
Date: September, 13 2018 09:05
Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing
TORONTO, ON / ACCESSWIRE / September 11, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targ...
Source: ACCESSWIRE
Date: September, 11 2018 07:15
Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
FDA updates on multifaceted plan to combat opioid crisis
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:44

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.23990.2250.23990.2126499,462
2018-12-100.27510.2470.27510.23021,123,799
2018-12-070.2850.26730.2868740.26631,097,964
2018-12-060.28990.2914750.29790.266937,493
2018-12-050.31060.300.340.30799,838

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1123,272221,64710.4996Cover
2018-12-10183,860323,20356.8868Short
2018-12-07142,158348,70740.7672Short
2018-12-06122,269336,84236.2986Short
2018-12-04124,171239,20151.9107Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IPCI.


About Intellipharmaceutics International Inc. (NASDAQ: IPCI)

Logo for Intellipharmaceutics International Inc. (NASDAQ: IPCI)

Not available

 

Contact Information

 

 

Current Management

  • Glen Neumann / IR

Current Share Structure

  • Market Cap: $14,784,123 - 05/17/2018
  • Issue and Outstanding: 34,704,515 - 11/30/2017

 


Recent Filings from (NASDAQ: IPCI)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 13 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: September, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: September, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 15 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: August, 15 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: August, 09 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: August, 08 2018
This filing is a pre-effective amendment to an F-1 filing
Filing Type: F-1/AFiling Source: edgar
Filing Date: August, 03 2018
This filing is a pre-effective amendment to an F-1 filing
Filing Type: F-1/AFiling Source: edgar
Filing Date: August, 03 2018

 

 


Daily Technical Chart for (NASDAQ: IPCI)

Daily Technical Chart for (NASDAQ: IPCI)


Stay tuned for daily updates and more on (NASDAQ: IPCI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IPCI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IPCI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IPCI and does not buy, sell, or trade any shares of IPCI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/